Processa (PCSA) CEO George Ng Receives 9,384 RSUs (Award)

What Happened

• George K. Ng, Chief Executive Officer of Processa Pharmaceuticals, was granted 9,384 restricted stock units (RSUs) on July 26, 2026. The RSUs are reported at $0.00 per share (no cash paid) and are a derivative award representing the right to receive Processa common stock in the future.

Key Details

• Transaction date: 2026-07-26; Form 4 filed: 2026-07-28 (timely filing).
• Instrument: Restricted Stock Units (derivative award), 9,384 RSUs; reported acquisition price $0.00 (award/grant).
• Vesting/distribution: The RSUs vested upon grant but will not be distributed until the earlier of (i) termination, (ii) six months after grant, (iii) a change of control, or (iv) the holder’s death (footnote F1).
• Related notes: Filing reflects the company’s 1-for-25 reverse stock split effective Dec 17, 2025 (footnote F3). Footnote F2 describes option vesting schedules but does not apply to this RSU grant.
• Shares owned after transaction: Not specified in the provided excerpt; see the full Form 4 for total beneficial ownership.

Context

• RSUs are a form of compensation: they give the holder a contingent right to receive shares later rather than an immediate purchase. Because these RSUs vested on grant but have delayed distribution, this is primarily a compensation event rather than an open‑market buy or sell and does not by itself signal immediate insider buying or selling.
• No cash changed hands and no sale occurred. For investors tracking insider buying as a bullish signal, awards like this are informative about executive compensation but less directly informative about the insider’s personal market conviction.